Stem Cell Institute is one of the world’s leading adult stem cell therapy and research centers. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of allogeneic human umbilical cord stem cells and autologous bone marrow stem cells to treat diseases and conditions listed below.
We have performed over 10,000 procedures since 2006 and we are accepting patients today.
Christian Diaz, MD is a staff physician at the Stem Cell Institute in Panama City, Panama. In this lecture, Dr. Diaz displays several photos of the clinic and medical staff. He then delves into autism spectrum disorder by outlining currently available autism treatments. He discusses a couple scientific articles about stem cell therapy for autism including the now-recently published one from Stem Cell Institute. Dr. Diaz describes the 5-day autism treatment protocol in Panama. He then moves on to follow-up results garnered from our patient registry. These results include ATEC scores and adverse events. Dr. Diaz does the same for multiple sclerosis treatments: scientific article reviews including the MS clinical trial that was conducted at Stem Cell Institute, MS treatment protocol at our clinic, and follow-up data including efficacy measurements and adverse events.
The Stem Cell Institute YouTube Site, here...
He is the founder and chairman of Medistem Panama, Inc., a leading stem cell laboratory and research facility located in the Technology Park of the prestigious City of Knowledge in Panama City, Panama. Medistem Panama (est. 2007) is at the forefront of research on the effects of adult stem cells on the course of several chronic diseases and conditions. The stem cell laboratory at Medistem Panama is fully licensed by the Ministry of Health of Panama.
Human umbilical cord tissue-derived mesenchymal stem cells (hUCT-MSCs) that were isolated and grown at Medistem Panama to create master cell banks are currently being used in the United States. These cells serve as the starting material for cellular products used in MSC clinical trials for two Duchenne’s muscular dystrophy patients under US FDA’s designation of Investigational New Drug (IND) for single patient compassionate use. (IND 16026 DMD Single Patient) These trials are the first in the United States to use hUCT-MSCs. Translational Biosciences, a fully-owned subsidiary of Medistem Panama is currently conducting phase I/II clinical trials for multiple sclerosis, autism and rheumatoid arthritis.
Dr. Riordan is founder, chairman and chief science officer of the Stem Cell Institute in Panama, which specializes in the treatment of human diseases and conditions with adult stem cells, primarily human umbilical cord tissue-derived mesenchymal stem cells. Established in 2007, Stem Cell Institute is one of the oldest, most well-known and well-respected stem cell therapy clinics in the world.
He is co-founder and chief science officer of the Riordan Medical Institute (RMI). Located in the Dallas-Fort Worth area city of Southlake, Texas, RMI specializes in the treatment of orthopedic conditions with autologous bone marrow-derived stem cells combined with amniotic tissue products developed by Dr. Riordan.
He is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals. Dr. Riordan’s team developed the product Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.
Dr. Riordan has published more than 70 scientific articles in international peer-reviewed journals. In the stem cell arena, his colleagues and he have published more than 20 articles on multiple sclerosis, spinal cord injury, heart failure, rheumatoid arthritis, Duchenne muscular dystrophy, autism, and Charcot-Marie-Tooth syndrome. In 2007, Dr. Riordan’s research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the “Medical Article of the Year Award” from Biomed Central. Other notable journals in which Dr. Riordan has published articles include the British Journal of Cancer, Cellular Immunology, Journal of Immunotherapy, and Translational Medicine.
In addition to his scientific journal publications, Dr. Riordan has authored two books about mesenchymal stem cell therapy: Stem Cell Therapy: A Rising Tide: How Stem Cells Are Disrupting Medicine and Transforming Lives and MSC (Mesenchymal Stem Cells): Clinical Evidence Leading Medicine’s Next Frontier. Dr. Riordan has also written two scientific book chapters on the use of non-controversial stem cells from placenta and umbilical cord.
Dr. Riordan is an established inventor. He is the inventor or co-inventor on more than 25 patent families, including 11 issued patents. His team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and University of Nebraska.
He has made a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father, Dr. Hugh Riordan, on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin C’s preferential toxicity to cancer cells notably led to a 1997 patent for the treatment of cancer with vitamin C. In 2010, Dr. Riordan was granted an additional patent for a new cellular vaccine for cancer patients.
Neil Riordan, PA, PhD earned his Bachelor of Science at Wichita State University and graduated summa cum laude. He received his Master’s degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.